Outcomes of Patients with Down Syndrome and <i>CRLF2</i>-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Karen R. Rabin(Children's Cancer Center), Stephen P. Hunger(Children's Hospital of Philadelphia), Mignon L. Loh(Seattle Children's Hospital), Brent L. Wood(University of Southern California), Reuven J. Schore(Children's National), Eric Larsen(University of Massachusetts Chan Medical School), Elizabeth A. Raetz(NYU Langone Health), Johann Hitzler(University of Toronto), Anne Angiolillo(Children's National), Yunfeng Dai(University of Florida), Kathryn G. Roberts(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Naomi Winick(The University of Texas Southwestern Medical Center), Cheryl L. Willman(Mayo Clinic), Shalini C. Reshmi(National Institutes of Health), Sarah K. Tasian(Children's Hospital of Philadelphia), Richard C. Harvey(University of New Mexico), Andrew J. Carroll(University of Alabama at Birmingham), Michael J. Burke(Children's Hospital of Wisconsin), I-Ming L. Chen(University of New Mexico), Kelly W. Maloney(Children's Hospital Colorado), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Zhiguo Chen(University of Florida), Michael J. Borowitz(Johns Hopkins University), Wanda L. Salzer(Maine Medical Center), Nyla A. Heerema(The Ohio State University), Julie M. Gastier‐Foster(Nationwide Children's Hospital)
Blood
November 4, 2020
Cited by 2


Related Papers